Want to see FR:ABVX full AI Analyst Report?
Abivax SA (ABVX) Stock Statistics & Valuation Metrics
Total Valuation
Abivax SA has a market cap or net worth of EUR 6.92B. The enterprise value is EUR 8.80B.
- Market Cap
- EUR 6.92B
- Enterprise Value
- EUR 8.80B
Share Statistics
Abivax SA has 87,548,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 87,548,100
- Owned by Insiders
- ―
- Owned by Institutions
- 12.24%
Financial Efficiency
Abivax SA’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -47.96%.
- Return on Equity (ROE)
- -0.74
- Return on Assets (ROA)
- -0.58
- Return on Invested Capital (ROIC)
- -47.96%
- Return on Capital Employed (ROCE)
- -0.48
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.43M
- Employee Count
- 98
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Abivax SA is -16.15. Abivax SA’s PEG ratio is 0.29.
- PE Ratio
- -16.15
- PS Ratio
- -3300.71
- PB Ratio
- 16.54
- Price to FCF
- -45.09
- Price to Operating Cash Flow
- -41.08
- PEG Ratio
- 0.29
Income Statement
In the last 12 months, Abivax SA had revenue of 0 and earned -336.10M in profits. Earnings per share was -4.83.
- Revenue
- 0
- Gross Profit
- -1.07M
- Operating Income
- -250.63M
- Pretax Income
- -333.31M
- Net Income
- -336.10M
- EBITDA
- -249.55M
- Earnings Per Share (EPS)
- -4.83
Cash Flow
In the last 12 months, operating cash flow was -147.46M and capital expenditures -191,000, giving a free cash flow of -147.65M billion.
- Operating Cash Flow
- -147.46M
- Free Cash Flow
- -147.65M
- Free Cash Flow per Share
- -1.85
Dividends & Yields
Abivax SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.22%
- Earnings Yield
- -5.82%
Stock Price Statistics
- Beta
- 1.30
- 52-Week Price Change
- -16.34%
- 50-Day Moving Average
- 88.03
- 200-Day Moving Average
- 98.92
- Relative Strength Index (RSI)
- 38.09
- Average Volume (3m)
- 125.91K
Important Dates
Abivax SA upcoming earnings date is Dec 14, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 21, 2026
- Next Earnings Date
- Dec 14, 2026
- Ex-Dividend Date
- ―
Financial Position
Abivax SA as a current ratio of 8.75, with Debt / Equity ratio of 7.05%
- Current Ratio
- 8.75
- Quick Ratio
- 8.75
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.94
- Interest Coverage Ratio
- -8.79
Taxes
In the past 12 months, Abivax SA has paid 2.79M in taxes.
- Income Tax
- 2.79M
- Effective Tax Rate
- -0.01
Enterprise Valuation
Abivax SA EV to EBITDA ratio is -22.48, with an EV/FCF ratio of -42.47.
- EV to Sales
- -3108.95
- EV to EBITDA
- -22.48
- EV to Free Cash Flow
- -42.47
- EV to Operating Cash Flow
- -42.52
Balance Sheet
Abivax SA has EUR 410.68M in cash and marketable securities with EUR 1.21M in debt, giving a net cash position of EUR 409.47M billion.
- Cash & Marketable Securities
- EUR 410.68M
- Total Debt
- EUR 1.21M
- Net Cash
- EUR 409.47M
- Net Cash Per Share
- EUR 4.68
- Tangible Book Value Per Share
- EUR 4.28
Margins
Gross margin is 153.15%, with operating margin of 11950.42%, and net profit margin of 17488.89%.
- Gross Margin
- 153.15%
- Operating Margin
- 11950.42%
- Pretax Margin
- 17651.91%
- Net Profit Margin
- 17488.89%
- EBITDA Margin
- 13830.74%
- EBIT Margin
- 13867.48%
Analyst Forecast
The average price target for Abivax SA is EUR 131.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 131.00
- Price Target Upside
- 72.26% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- ―
- AI Score
- 44
